Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/98110
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pisaniello, A.D. | - |
dc.contributor.author | Scherer, D.J. | - |
dc.contributor.author | Kataoka, Y. | - |
dc.contributor.author | Nicholls, S.J. | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Expert Opinion on Pharmacotherapy, 2015; 16(3):347-356 | - |
dc.identifier.issn | 1465-6566 | - |
dc.identifier.issn | 1744-7666 | - |
dc.identifier.uri | http://hdl.handle.net/2440/98110 | - |
dc.description.abstract | Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients. Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established therapies and new agents in development that target a range of lipid factors. Expert opinion: More intensive efforts are required to ensure that statin use is maximized in higher risk patients. A range of novel therapies, including proprotein convertase subtilisin kexin-type 9 and cholesteryl ester transfer protein inhibitors, may provide additional protection, although this remains to be established by clinical trials. | - |
dc.description.statementofresponsibility | Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka and Stephen J Nicholls | - |
dc.language.iso | en | - |
dc.publisher | Taylor and Francis | - |
dc.rights | © 2015 Informa UK, Ltd. ISSN 1465-6566, e-ISSN 1744-7666 All rights reserved: reproduction in whole or in part not permitted | - |
dc.source.uri | http://dx.doi.org/10.1517/14656566.2014.986094 | - |
dc.subject | Atherosclerosis; cardiovascular risk; lipid-modifying therapy; lipids | - |
dc.title | Ongoing challenges for pharmacotherapy for dyslipidemia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1517/14656566.2014.986094 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Pisaniello, A.D. [0000-0002-4117-6200] | - |
dc.identifier.orcid | Scherer, D.J. [0000-0002-7016-7469] | - |
dc.identifier.orcid | Nicholls, S.J. [0000-0002-9668-4368] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.